Troubles of Two Landmark Cancer Drugs, Celebrex and Iressa, Likely to Shape cancer Prevention, FDA Policy. FDA Mulls Withdrawal of Iressa.
Also in This 8-page Issue: President Bush Nominates EPA Administrator Michael Leavitt for HHS Secretary.
NCI Selects 15 Awardees to Operate the Cancer Information Service.
American Legacy Foundation Says Group is Fighting For Its Survival.
Funding Opportunities Listed.
Trending Stories
- With five-year cancer survival at an all-time high, does this mean people are living longer?
- Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
- An oncologist navigates terminal sarcoma, insurmountable debt, and “a legacy of grief”
How colleagues and Fargo, ND, neighbors came together to help the Erickson-Abou Zahrs - Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched - House passes three-year extension of ACA subsidies with bipartisan support
- When “safe and effective” is not “reasonable and necessary”
We can curb excessive drug dosing and improve the quality of cancer care









